Literature DB >> 25124380

Beta-lactam hypersensitivity and cross-reactivity.

Adrienne T Terico1, Jason C Gallagher2.   

Abstract

Penicillin is the most frequently reported cause of drug allergy, and cross-reactivity of penicillins with other beta-lactam antibiotics is an area of debate. This review evaluates the available data on immunoglobulin E-mediated penicillin hypersensitivity and cross-reactivity with cephalosporin, carbapenem, and monobactam antibiotics. A MEDLINE search was conducted from 1950 to October 2013, and selected references from review articles were also evaluated. There is a wide variety in reported incidences of cross-reactivity between penicillins and cephalosporins or carbapenems, with early retrospective studies suggesting up to 41.7% and 47.4% cross-reactivity, respectively. Conversely, the use of monobactam antibiotics is frequently employed in the case of a penicillin allergy, as prescribers believe that there is no cross-reactivity between the 2 drug classes. More recent prospective studies suggest that the rates of cross-reactivity with cephalosporins and carbapenems are <5% and <1%, respectively. Similarities in penicillin and cephalosporin side chains may play a role in cross-reactivity between these classes. Cross-reactivity with monobactams is essentially negligible; however, there are some clinical data to support an interaction between ceftazidime and aztreonam, due to the similarity of their side chains. The data reviewed suggest that avoidance of other beta-lactams in patients with type 1 hypersensitivity to penicillins should be reconsidered.
© The Author(s) 2014.

Entities:  

Keywords:  beta-lactam; cross-reactivity; hypersensitivity; penicillin

Mesh:

Substances:

Year:  2014        PMID: 25124380     DOI: 10.1177/0897190014546109

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  10 in total

1.  Pairwise antibiotic interactions in Escherichia coli: triclosan, rifampicin and aztreonam with nine other classes of antibiotics.

Authors:  Caroline Nguyen; Alice Zhou; Ayesha Khan; Jeffrey H Miller; Pamela Yeh
Journal:  J Antibiot (Tokyo)       Date:  2016-03-09       Impact factor: 2.649

2.  A General LC-MS/MS Method for Monitoring Potential β-Lactam Contamination in Drugs and Drug-Manufacturing Surfaces.

Authors:  Chen Qiu; Hongbin Zhu; Connie Ruzicka; David Keire; Hongping Ye
Journal:  AAPS J       Date:  2018-05-15       Impact factor: 4.009

3.  Anaphylactic shock caused by intramuscular injection of midazolam during the perioperative period: a case report.

Authors:  Kyu Nam Kim; Dong Won Kim; Yeong Hun Sin; Soo Kyung Lee
Journal:  Korean J Anesthesiol       Date:  2016-08-18

4.  Higher risk of revision for infection using systemic clindamycin prophylaxis than with cloxacillin.

Authors:  Otto Robertsson; Olof Thompson; Annette W-Dahl; Martin Sundberg; Lars Lidgren; Anna Stefánsdóttir
Journal:  Acta Orthop       Date:  2017-05-11       Impact factor: 3.717

Review 5.  Overview and Insights into Carbapenem Allergy.

Authors:  Yuman Lee; Nicole Bradley
Journal:  Pharmacy (Basel)       Date:  2019-08-08

Review 6.  Antibiotic Hypersensitivity Mechanisms.

Authors:  Jenana H Maker; Cassandra M Stroup; Vanthida Huang; Stephanie F James
Journal:  Pharmacy (Basel)       Date:  2019-08-27

Review 7.  Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity.

Authors:  Saira B Chaudhry; Michael P Veve; Jamie L Wagner
Journal:  Pharmacy (Basel)       Date:  2019-07-29

Review 8.  Bacteriophages as Alternatives to Antibiotics in Clinical Care.

Authors:  Danitza Romero-Calle; Raquel Guimarães Benevides; Aristóteles Góes-Neto; Craig Billington
Journal:  Antibiotics (Basel)       Date:  2019-09-04

9.  Preoperative β-lactam antibiotic prophylaxis is superior to bacteriostatic alternatives in immediate expander-based breast reconstruction.

Authors:  Travis J Miller; Austin C Remington; Dung H Nguyen; Geoffrey C Gurtner; Arash Momeni
Journal:  J Surg Oncol       Date:  2021-07-08       Impact factor: 2.885

10.  The Impact of Penicillin Skin Testing on Aztreonam Stewardship and Cost Savings in Immunocompromised Cancer Patients.

Authors:  Farnaz Foolad; Sheila Berlin; Candice White; Emma Dishner; Ying Jiang; Mahnaz Taremi
Journal:  Open Forum Infect Dis       Date:  2019-08-23       Impact factor: 3.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.